Tesamorelin, a stabilized GHRH (growth hormone–releasing hormone) analog developed by Theratechnologies, is the only FDA-approved GHRH peptide with completed Phase III clinical trial data. This article reviews tesamorelin's mechanism, the visceral fat reduction findings, and its expanding off-label research interest in 2026.
Tesamorelin is a synthetic 44-amino-acid peptide analog of native GHRH, modified with chemical substitutions to resist enzymatic degradation and permit chronic dosing. It binds GHRH receptors in the anterior pituitary, stimulating the release of endogenous growth hormone. Unlike growth hormone itself (which is FDA-controlled and carries strict regulations), tesamorelin is an secretagogue—it induces the body's own hormone release.
Tesamorelin was FDA-approved in 2010 for HIV-associated lipodystrophy (abnormal fat distribution) under the brand name Egrifta. The approval was based on two pivotal Phase 3 trials—LIPO-010 and CTR-1011—demonstrating 15–18% reduction in visceral adipose tissue (VAT) over 12 weeks without diet changes, accompanied by measurable increases in IGF-1 and improvements in cardiovascular risk markers.
Tesamorelin has garnered growing research interest for non-HIV conditions involving metabolic dysfunction and visceral obesity. Off-label use is being explored in:
However, most clinical evidence is in HIV patients; the generalizability to other populations remains investigational.
We supply high-purity peptides for preclinical research:
Universe Peptide publishes research-focused education for the scientific community. Products are for laboratory research only. See more in our News & research updates.